Related Experiment Video

Updated: Jun 1, 2026

Isolation, Transfection, and Culture of Primary Human Monocytes
09:13

Isolation, Transfection, and Culture of Primary Human Monocytes

Published on: December 16, 2019

Lipid metabolism in treated HIV Infection

Michael P Dubé1, Joseph J Cadden

  • 1The Division of Infectious Diseases and the Department of Medicine, University of Southern California, Keck School of Medicine, 5P21 Rand Schrader Health and Research Clinic, Los Angeles, CA 90033, USA. mdube@usc.edu

Best Practice & Research. Clinical Endocrinology & Metabolism
|June 14, 2011
PubMed

Insights

Human immunodeficiency virus (HIV) infection and its treatments can cause lipid disorders, increasing cardiovascular disease risk. Management should align with general guidelines, carefully considering drug interactions for HIV patients.

Area of Science:

  • Medical Science
  • Pharmacology
  • Cardiology

Background:

  • HIV infection and antiretroviral therapy (ART) are associated with significant lipid and lipoprotein disturbances.
  • These dyslipidemias contribute to the elevated cardiovascular disease (CVD) risk observed in HIV-infected individuals.
  • Understanding these metabolic alterations is crucial for comprehensive patient care.

Purpose of the Study:

  • To review the impact of HIV infection and ART on lipid metabolism.
  • To summarize the lipid-altering potential of various antiretroviral drugs.
  • To propose an intervention strategy for managing dyslipidemia in HIV patients.

Main Methods:

  • Literature review focusing on studies investigating lipid profiles in HIV-infected patients.
  • Analysis of the effects of different classes of antiretroviral agents on lipid levels.
  • Synthesis of current guidelines for dyslipidemia management.

Main Results:

  • Both HIV infection and specific antiretroviral drugs can independently or synergistically dysregulate lipid metabolism.
  • Certain antiretroviral agents exhibit a higher propensity to induce hyperlipidemia compared to others.
  • Potential for adverse drug interactions between lipid-lowering agents and ART exists.

Conclusions:

  • Dyslipidemia management in HIV-infected individuals should generally follow established guidelines for the general population.
  • Careful consideration of drug-drug interactions between lipid-lowering medications and antiretroviral drugs is paramount.
  • A tailored approach is necessary to optimize lipid management and reduce cardiovascular risk in this cohort.

More Related Videos

A Simple Flow Cytometric Method to Measure Glucose Uptake and Glucose Transporter Expression for Monocyte Subpopulations in Whole Blood06:28

A Simple Flow Cytometric Method to Measure Glucose Uptake and Glucose Transporter Expression for Monocyte Subpopulations in Whole Blood

Published on: August 12, 2016

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Lipid Catabolism01:25

Lipid Catabolism

Triglycerides serve as crucial long-term energy storage molecules in microorganisms, providing a dense source of metabolic energy. Their breakdown is mediated by lipases, which hydrolyze triglycerides into glycerol and free fatty acids. Each of these components follows distinct metabolic pathways, ultimately contributing to ATP synthesis and cellular energy homeostasis.Glycerol MetabolismGlycerol, released from triglyceride hydrolysis, is phosphorylated by glycerol kinase to form...